Harvard Bioscience Inc. (NASDAQ:HBIO) saw strong trading volume on Monday . 165,790 shares traded hands during trading, an increase of 42% from the previous session’s volume of 116,515 shares.The stock last traded at $2.63 and had previously closed at $2.61.

Separately, Zacks Investment Research lowered shares of Harvard Bioscience from a “hold” rating to a “sell” rating in a report on Tuesday, August 2nd.

The stock’s 50-day moving average is $2.67 and its 200 day moving average is $2.97. The firm’s market cap is $93.33 million.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. Harvard Bioscience had a negative net margin of 18.04% and a positive return on equity of 3.40%. The company earned $26.10 million during the quarter, compared to analysts’ expectations of $26.60 million. On average, equities research analysts predict that Harvard Bioscience Inc. will post $0.16 EPS for the current year.

A number of hedge funds have recently made changes to their positions in HBIO. First Light Asset Management LLC raised its position in Harvard Bioscience by 27.4% in the second quarter. First Light Asset Management LLC now owns 2,740,203 shares of the company’s stock valued at $7,837,000 after buying an additional 590,010 shares during the last quarter. Heartland Advisors Inc. raised its position in Harvard Bioscience by 7.1% in the second quarter. Heartland Advisors Inc. now owns 2,200,000 shares of the company’s stock valued at $6,292,000 after buying an additional 145,778 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Harvard Bioscience by 0.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,609,704 shares of the company’s stock valued at $4,604,000 after buying an additional 14,198 shares during the last quarter. Royce & Associates LP raised its position in Harvard Bioscience by 17.0% in the first quarter. Royce & Associates LP now owns 1,546,000 shares of the company’s stock valued at $4,669,000 after buying an additional 225,000 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Harvard Bioscience by 3.1% in the second quarter. Acadian Asset Management LLC now owns 729,779 shares of the company’s stock valued at $2,088,000 after buying an additional 21,961 shares during the last quarter. 66.31% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.

5 Day Chart for NASDAQ:HBIO

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.